At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITCI Intra-Cellular Therapies
Market Closed 05-17 16:00:00 EDT
65.00
-1.53
-2.30%
盘后65.00
+0.000.00%
16:58 EDT
High66.88
Low64.92
Vol783.43K
Open66.88
D1 Closing66.53
Amplitude2.95%
Mkt Cap6.86B
Tradable Cap6.63B
Total Shares105.57M
T/O51.33M
T/O Rate0.77%
Tradable Shares102.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Maintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study Outlook
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.